Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZIMMER BIOMET HOLDINGS, INC.

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zimmer Biomet Holdings, Inc. Announces New Data Supporting Clinical Benefits of Mymobility® with Apple Watch® At AAOS 2021

08/31/2021 | 10:00am EDT

Zimmer Biomet Holdings, Inc. announced four data presentations on the clinical value of mymobility® with Apple Watch®, a first-of-a-kind remote care management platform designed to help healthcare professionals remotely support and guide patients as they prepare for and recover from orthopedic procedures. mymobility with Apple Watch is a part of ZBEdge™, Zimmer Biomet's suite of connected digital and robotic technologies designed to deliver actionable insights with the goal of improving patient outcomes. The data are being presented at the American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting being held on August 31 to September 3 in San Diego. PODIUM SESSION: Paper 458 - A Smartwatch Paired Mobile Application Provides Postoperative Self-Directed Rehabilitation Without Compromising Patient Outcomes: A Randomized Controlled Trial: Evaluated 337 patients who underwent primary total knee arthroplasty (TKA) to determine the impact on postoperative outcomes with the use of a self-directed rehabilitation (SDR) program after TKA. The SDR was administered via the mymobility application which provided pre- and post-operative education and video-directed exercise programs and was paired with an Apple Watch to help track the patient's physical activity. Patients were divided into three groups: a control group who had formal physical therapy (184 patients), a high exercise-compliance SDR treatment group (90 patients) and a low exercise-compliance SDR group (63 patients). Patient reported outcome measures (PROMs) of knee injury and osteoarthritis outcome scores, joint replacement (KOOS, JR) along with knee range of motion and manipulation rates were evaluated. Results showed no clinically significant differences between groups for all evaluated outcomes at 3, 6 or 12 months. Study Outcome: Researchers concluded that a postoperative SDR program administered through a mobile application paired with a smartwatch can provide similar patient-reported outcome measures while not affecting manipulation rates or compromising range of motion, regardless of the level of compliance with the application exercise program.


© S&P Capital IQ 2021
All news about ZIMMER BIOMET HOLDINGS, INC.
10/07ZIMMER BIOMET : Announces Webcast and Conference Call of Third Quarter 2021 Financial Resu..
PR
10/05ZIMMER BIOMET : Barclays Cuts Price Target on Zimmer Biomet to $186 From $210, Keeps Overw..
MT
09/29ZIMMER BIOMET HOLDINGS, INC. : Ex-dividend day for
FA
09/28WALL STREET STOCK EXCHANGE : Is inflation still transitionary?
09/28ANALYST RECOMMENDATIONS : 888, Chesapeake Energy, Conocophillips, Marathon Oil, Playtech....
09/27ZIMMER BIOMET : Needham Lowers PT for Zimmer Biomet Holdings to $187 From $202 Given Impac..
MT
09/15ZIMMER BIOMET : Announces Key Additions to 'NewCo' Leadership Team, Transaction to Form Ne..
AQ
09/14ZIMMER BIOMET : Names Finance Chief for Company Spin-Off
MT
09/14ZIMMER BIOMET : Announces Key Additions to "NewCo" Leadership Team; Transaction to Form Ne..
PR
09/14Zimmer Biomet Holdings, Inc. Announces Executive Changes
CI
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 8 065 M - -
Net income 2021 967 M - -
Net Debt 2021 6 377 M - -
P/E ratio 2021 33,3x
Yield 2021 0,64%
Capitalization 31 414 M 31 414 M -
EV / Sales 2021 4,69x
EV / Sales 2022 4,27x
Nbr of Employees 20 000
Free-Float 66,7%
Chart ZIMMER BIOMET HOLDINGS, INC.
Duration : Period :
Zimmer Biomet Holdings, Inc. Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 150,42 $
Average target price 185,21 $
Spread / Average Target 23,1%
EPS Revisions
Managers and Directors
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Nitin Goyal Chief Science, Technology & Innovation Officer
Ivan Tornos Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZIMMER BIOMET HOLDINGS, INC.-2.38%31 414
ABBOTT LABORATORIES15.74%224 651
MEDTRONIC PLC5.08%165 656
BECTON, DICKINSON AND COMPANY-1.25%70 962
HOYA CORPORATION21.65%56 316
DEXCOM, INC.53.24%54 815